On Friday, Johnson & Johnson (NYSE:JNJ)’s shares declined -1.51% to $93.41.
Johnson & Johnson (JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, Oct. 13th, to review third-quarter results. Gary Pruden, Worldwide Chairman, Medical Devices; Dominic Caruso, Vice President, Finance and Chief Financial Officer and Louise Mehrotra, Vice President, Investor Relations, will host the call.
Johnson & Johnson, together with its auxiliaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices.
Kinder Morgan Inc (NYSE:KM)’s shares dropped -1.35% to $30.42.
Kinder Morgan, Inc. (KMI) declared it will extend its current binding open season to review shipper comments and interest received to date, in addition to continue to seek commitments for the projected Utica Marcellus Texas Pipeline (UMTP) project, which would transport natural gas liquids and condensate produced from the Utica and Marcellus basins to delivery points along the Texas Gulf Coast, counting connectivity to a Kinder Morgan dock located along the Houston Ship Channel. The binding open season planned to end recently will now end at 5 p.m. Central Time on Dec. 15, 2015.
The projected project would involve the abandonment and conversion of 964 miles of natural gas service on KMI’s existing Tennessee Gas Pipeline, the construction of about 200 miles of new pipeline from Louisiana to Texas, new storage in Ohio and 120 miles of new laterals to provide basin connectivity.
Kinder Morgan, Inc. operates as an energy infrastructure and energy company in North America. The company operates through Natural Gas Pipelines, CO2, Terminals, Products Pipelines, Kinder Morgan Canada, and Other segments.
At the end of Friday’s trade, International Business Machines Corp. (NYSE:IBM)‘s shares dipped -2.38% to $144.62.
Alior Bank recently declared it selected an IBM ( IBM) MobileFirst for iOS app to fundamentally transform the way customers in Poland interact with the bank. Using iPad, Alior’s banking professionals will provide customers with a dynamic and more personalized banking experience that taps into the power of analytics and is secure, easy, fast and accessible 24 hours a day.
Alior Bank will be the first bank in Poland to take advantage of IBM MobileFirst for iOS apps, providing its employees with secure, mobile access to individual customer data right on iPad so they can provide personalized recommendations and offers. By empowering employees with access to information and insight when and wherever they interact with customers, Alior Bank continues its commitment to lead the market in innovation.
International Business Machines Corporation provides information technology (IT) products and services worldwide. The company’s Global Technology Services segment provides IT infrastructure and business process services, such as outsourcing, processing, integrated technology, cloud, and technology support.
Geron Corporation (NASDAQ:GERN), ended its Friday’s trading session with -3.75% loss, and closed at $3.59.
Geron Corporation (GERN) stated financial results for the second quarter ended June 30, 2015.
Second Quarter 2015 Results
For the second quarter of 2015, the company stated a net loss of $9.4 million, or $0.06 per share, contrast to $8.7 million, or $0.06 per share, for the comparable 2014 period. Revenues for the second quarter of 2015 were $251,000 contrast to $341,000 for the comparable 2014 period. Interest and other income for the second quarter of 2015 amounted to $145,000 contrast to $99,000 for the comparable 2014 period. The company ended the second quarter of 2015 with $157.0 million in cash and investments.
Total operating expenses for the second quarter of 2015 were $9.7 million contrast to $9.0 million for the comparable 2014 period. Research and development expenses for the second quarter of 2015 were $4.8 million contrast to $5.2 million for the comparable 2014 period. General and administrative expenses for the second quarter of 2015 were $4.0 million contrast to $3.9 million for the comparable 2014 period. Operating expenses for the 2015 second quarter also comprised of restructuring charges of $941,000 in connection with the company’s organizational resizing declared in March 2015.
Geron Corporation, a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has partnership and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, counting hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
